|
Your Input:
|
||||
| BDKRB1 | B1 bradykinin receptor; This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation (353 aa) | |||
| PROKR2 | Prokineticin receptor 2; Receptor for prokineticin 2. Exclusively coupled to the G(q) subclass of heteromeric G proteins. Activation leads to mobilization of calcium, stimulation of phosphoinositide turnover and activation of p44/p42 mitogen-activated protein kinase (384 aa) | |||
| MLNR | Motilin receptor; Receptor for motilin; Belongs to the G-protein coupled receptor 1 family (412 aa) | |||
| GNRHR | Gonadotropin-releasing hormone receptor; Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle- stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol- calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling (328 aa) | |||
| KISS1R | KiSS-1 receptor; Receptor for metastin (kisspeptin-54 or kp-54), a C- terminally amidated peptide of KiSS1. KiSS1 is a metastasis suppressor protein that suppresses metastases in malignant melanomas and in some breast carcinomas without affecting tumorigenicity. The metastasis suppressor properties may be mediated in part by cell cycle arrest and induction of apoptosis in malignant cells. The receptor is essential for normal gonadotropin-released hormone physiology and for puberty. The hypothalamic KiSS1/KISS1R system is a pivotal factor in central regulation of the gonadotropic axis a [...] (398 aa) | |||
| GHSR | Growth hormone secretagogue receptor type 1; Receptor for ghrelin, coupled to G-alpha-11 proteins. Stimulates growth hormone secretion. Binds also other growth hormone releasing peptides (GHRP) (e.g. Met-enkephalin and GHRP-6) as well as non-peptide, low molecular weight secretagogues (e.g. L-692,429, MK-0677, adenosine) (366 aa) | |||
| MCHR1 | Melanin-concentrating hormone receptor 1; Receptor for melanin-concentrating hormone, coupled to both G proteins that inhibit adenylyl cyclase and G proteins that activate phosphoinositide hydrolysis; Belongs to the G-protein coupled receptor 1 family (422 aa) | |||
| CMA1 | Chymase; Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion (247 aa) | |||
| NMUR2 | Neuromedin-U receptor 2; Receptor for the neuromedin-U and neuromedin-S neuropeptides; Belongs to the G-protein coupled receptor 1 family (415 aa) | |||
| NMBR | Neuromedin-B receptor; Receptor for neuromedin-B; Bombesin receptors (390 aa) | |||
| HTR2B | 5-hydroxytryptamine receptor 2B; G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol- calcium second messenger system that modulates the activity [...] (481 aa) | |||
| GPR65 | Psychosine receptor; Receptor for the glycosphingolipid psychosine (PSY) and several related glycosphingolipids. Plays a role in immune response by maintaining lysosome function and supporting phagocytosis-mediated intracellular bacteria clearance. May have a role in activation-induced cell death or differentiation of T-cells (By similarity); G protein-coupled receptors, Class A orphans (337 aa) | |||
| HTR2C | 5-hydroxytryptamine receptor 2C; G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1- 2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathway [...] (458 aa) | |||
| NPFFR1 | Neuropeptide FF receptor 1; Receptor for NPAF (A-18-F-amide) and NPFF (F-8-F-amide) neuropeptides, also known as morphine-modulating peptides. Can also be activated by a variety of naturally occurring or synthetic FMRF-amide like ligands. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system (430 aa) | |||
| MCHR2 | Melanin-concentrating hormone receptor 2; Receptor for melanin-concentrating hormone, coupled to G proteins that activate phosphoinositide hydrolysis (340 aa) | |||
| CCR5 | C-C chemokine receptor type 5; Receptor for a number of inflammatory CC-chemokines including MIP-1-alpha, MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 R5 isolates (352 aa) | |||
| PTGER1 | Prostaglandin E2 receptor EP1 subtype; Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues; Belongs to the G-protein coupled receptor 1 family (402 aa) | |||
| CCKAR | Cholecystokinin receptor type A; Receptor for cholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. Has a 1000-fold higher affinity for CCK rather than for gastrin. It modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system (428 aa) | |||
| EDNRA | Endothelin-1 receptor; Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. The rank order of binding affinities for ET-A is- ET1 > ET2 >> ET3 (427 aa) | |||
| KEL | Kell blood group glycoprotein; Zinc endopeptidase with endothelin-3-converting enzyme activity. Cleaves EDN1, EDN2 and EDN3, with a marked preference for EDN3; Blood group antigens (732 aa) | |||
| EDN2 | Endothelin-2; Endothelins are endothelium-derived vasoconstrictor peptides; Endogenous ligands (178 aa) | |||
| ECE1 | Endothelin-converting enzyme 1; Converts big endothelin-1 to endothelin-1; Belongs to the peptidase M13 family (770 aa) | |||
| EDNRB | Endothelin receptor type B; Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system; Belongs to the G-protein coupled receptor 1 family. Endothelin receptor subfamily. EDNRB sub-subfamily (532 aa) | |||
| EDN1 | Endothelin-1; Endothelins are endothelium-derived vasoconstrictor peptides; Belongs to the endothelin/sarafotoxin family (212 aa) | |||
| MME | Neprilysin; Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids. Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond. Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9. Involved in the degradation of atrial natriuretic factor (ANF). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers; Belongs to the peptidase M13 family (750 aa) | |||
| ADM | ADM; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels; Endogenous ligands (185 aa) | |||
